palmyrolide A: neuroactive marine macrolide; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 60201959 |
| CHEMBL ID | 3358521 |
| MeSH ID | M0574472 |
| Synonym |
|---|
| palmyrolide a |
| CHEMBL3358521 |
| DTXSID301236348 |
Palmyrolide A is a neuroprotective macrolide isolated by Gerwick and coworkers in 2010.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Palmyrolide A is a neuroprotective macrolide isolated by Gerwick and coworkers in 2010. " | ( Synthesis and biological evaluation of palmyrolide A macrocycles as sodium channel blockers towards neuroprotection. Mehrotra, S; Murray, TF; Philkhana, SC; Reddy, DS, 2016) | 2.15 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1169941 | Antagonist activity against Voltage-gated sodium channel in Swiss-Webster mouse primary cerebrocortical neurons assessed as inhibition of veratridine-induced sodium influx by SBFI-AM dye based fluorescence assay | 2014 | Journal of natural products, Nov-26, Volume: 77, Issue:11 | Detailed analysis of (-)-palmyrolide a and some synthetic derivatives as voltage-gated sodium channel antagonists. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.43) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||